Two groups of scientists – led by researchers from Genentech Inc. and Beth Israel Deaconess Medical Center, respectively – have reported on why some cancer cells are resistant to drugs, such as Taxol, that target microtubules. Such drugs are among the most widely prescribed chemotherapeutic agents.